Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...

European Union trade chief Maros Sefcovic said on Thursday that his top priority in trade talks with President Donald Trump's ...

In the current market session, Regeneron Pharmaceuticals Inc. REGN share price is at $695.58, after a 0.06% decrease. Over the past month, the stock spiked by 2.93%, but over the past year, it ...

Regeneron Pharmaceuticals' fourth quarter results beat my and Wall Street analysts' expectations. See why REGN stock is a top ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

It’s now 3–1, with the First Circuit (2025) aligning with the Sixth (2023) and Eighth (2022) Circuits finding the meaning of the words ...

Regeneron is also embroiled in a securities fraud class action lawsuit stemming from a significant stock price drop on October 31, 2024. Shares plunged $84.59 that day, wiping out approximately $9 ...

Key Takeaways - The First Circuit ruled in United States v. Regeneron Pharmaceuticals, Inc., that the government must prove but-for causation ...

The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been ...

On April 10, 2024, the U.S. Department of Justice announced it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.